4 free views remaining today

Leydig cell hypoplasia

Description

Leydig Cell Hypoplasia: A Rare Condition Affecting Male Sexual Development

Leydig cell hypoplasia, also known as Leydig cell agenesis or aplasia, is a rare autosomal recessive genetic and endocrine syndrome that affects an estimated 1 in 1,000,000 individuals with XY chromosomes [1]. This condition is characterized by the underdevelopment (hypoplasia) of Leydig cells in the testes, which are responsible for secreting male sex hormones (androgens) essential for normal male sexual development before birth and during puberty [2].

Key Features

  • Underdevelopment or absence of Leydig cells in the testes
  • Reduced production of male sex hormones (androgens)
  • Impaired normal male sexual development
  • Rare autosomal recessive genetic disorder

Symptoms

The severity of Leydig cell hypoplasia can vary, but it often manifests with symptoms such as:

  • Low serum testosterone levels
  • Lack of virilization (development of male characteristics)
  • Lack of spermatogenesis (production of sperm)

In severe cases, the condition can lead to complete 46,XY male pseudohermaphroditism, characterized by a lack of responsiveness to luteinizing hormone (LH) and human chorionic gonadotropin (hCG) [11].

Causes

The exact cause of Leydig cell hypoplasia is not fully understood, but it is believed to be related to mutations in the LHCGR gene, which codes for the luteinizing hormone receptor. These mutations can lead to impaired Leydig cell differentiation and testosterone production [12].

References

[1] Description of Leydig cell hypoplasia as a rare autosomal recessive genetic and endocrine syndrome affecting 1 in 1,000,000 individuals with XY chromosomes. [2] Leydig cells secrete male sex hormones (androgens) essential for normal male sexual development before birth and during puberty. [11] Complete 46,XY male pseudohermaphroditism characterized by a lack of responsiveness to luteinizing hormone (LH) and human chorionic gonadotropin (hCG). [12] Mutations in the LHCGR gene leading to impaired Leydig cell differentiation and testosterone production.

Additional Characteristics

  • Rare autosomal recessive genetic disorder
  • Leydig cell hypoplasia, also known as Leydig cell agenesis or aplasia
  • A rare autosomal recessive genetic and endocrine syndrome that affects an estimated 1 in 1,000,000 individuals with XY chromosomes
  • Characterized by the underdevelopment (hypoplasia) of Leydig cells in the testes
  • Responsible for secreting male sex hormones (androgens) essential for normal male sexual development before birth and during puberty
  • Reduced production of male sex hormones (androgens)
  • Impaired normal male sexual development
  • Low serum testosterone levels
  • Lack of virilization (development of male characteristics)
  • Lack of spermatogenesis (production of sperm)
  • Complete 46,XY male pseudohermaphroditism characterized by a lack of responsiveness to luteinizing hormone (LH) and human chorionic gonadotropin (hCG)

Signs and Symptoms

Symptoms of Leydig Cell Hypoplasia

Leydig cell hypoplasia is a rare genetic disorder that affects male sexual development. The symptoms of this condition can vary in severity, but they often include:

  • Abnormal genitalia: Individuals with Leydig cell hypoplasia may be born with female or ambiguous external genitalia, which can make it difficult to determine their sex at birth.
  • Small penis (micropenis): One of the most common symptoms is a small penis, which can range from mildly underdeveloped to severely undersized.
  • Hypospadias: The opening of the urethra may be located on the underside of the penis instead of the tip.
  • Cryptorchidism (undescended testes): In some cases, one or both testicles may not have descended into their proper position in the scrotum.
  • Delayed or absent puberty: Individuals with Leydig cell hypoplasia may experience delayed or absent puberty, which can lead to infertility and other reproductive issues.

Other symptoms

In addition to these physical symptoms, individuals with Leydig cell hypoplasia may also experience:

  • Female gender identity or gender variance: Some individuals may identify as female or exhibit feminine behaviors.
  • Hypergonadotropic hypogonadism: This condition is characterized by high levels of gonadotropins (hormones that stimulate the production of sex hormones) despite low levels of sex hormones.

References

  • [1] Leydig cell hypoplasia is a rare form of male pseudohermaphroditism in which individuals with a 46,XY karyotype are born with complete female or mildly virilized external genitalia and fail to develop secondary sexual characteristics at puberty.
  • [5] Affected males may have a small penis (micropenis), the opening of the urethra on the underside of the penis (hypospadias), or a scrotum divided into two lobes.
  • [6] Individuals with LCH may have a small penis (micropenis),the opening of the urethra on the underside of the penis (hypospadias), or undescended testes.
  • [11] Leydig cell hypoplasia (LCH) is a disorder that impairs male sexual development. It causes incomplete development of Leydig cells, which are cells in the testicles (testes) that secrete male sex hormones (androgens).

Additional Symptoms

  • Hypospadias
  • Abnormal genitalia
  • Delayed or absent puberty
  • Cryptorchidism (undescended testes)
  • Small penis (micropenis)
  • Female gender identity or gender variance
  • Hypergonadotropic hypogonadism

Diagnostic Tests

Diagnostic Tests for Leydig Cell Hypoplasia

Leydig cell hypoplasia (LCH) is a rare genetic disorder that affects male sexual development. Diagnosing LCH can be challenging, but several diagnostic tests can help confirm the condition.

  • Genetic Testing: Genetic testing is the primary method of diagnosing LCH. It involves analyzing a patient's DNA for mutations in the LHCGR gene, which is responsible for testosterone production. This test can identify the genetic mutation that causes LCH (Citations: [4], [13]).
  • Hormone Level Tests: Hormone level tests are used to assess the levels of testosterone and other hormones in the body. These tests can help determine if there is a deficiency or imbalance of these hormones, which is characteristic of LCH (Citations: [11], [12]).
  • Stimulation Testing: Stimulation testing involves administering human chorionic gonadotropin (hCG) to stimulate testosterone production. This test can help confirm the diagnosis of LCH by measuring the response to hCG stimulation (Citations: [3], [11]).
  • Histopathology: Histopathology is a microscopic examination of tissue samples, which can provide evidence of Leydig cell hypoplasia. This test involves examining tissue samples from the testes or other affected areas (Citations: [9], [15]).

Additional Tests

In some cases, additional tests may be performed to assess hormone levels and evaluate the function of other cells involved in testosterone production. These tests can include:

  • ACTH Test: A short ACTH test is used to measure adrenal steroid production (Citation: [12]).
  • GnRH-Stimulated Gonadotropin Values: Basal and GnRH-stimulated gonadotropin values are elevated in pubertal subjects with LCH (Citation: [11]).

Diagnostic Teams

A diagnostic team for Leydig cell hypoplasia may include:

  • Endocrinology: Endocrinologists specialize in hormone-related disorders, including LCH.
  • Genetics: Geneticists can provide expertise on genetic testing and counseling.
  • Urology: Urologists can assess the reproductive system and provide guidance on fertility issues.

It's essential to consult with a qualified specialist for accurate diagnosis and treatment of Leydig cell hypoplasia.

Treatment

Leydig cell hypoplasia (LCH) is a rare genetic disorder that affects male sexual development, characterized by underdevelopment of Leydig cells in the testes [2]. While there is no specific treatment or cure for LCH, various drug treatments have been explored to manage its symptoms.

Testosterone Therapy In individuals raised as males, testosterone therapy is often initiated at puberty to promote phallic growth and secondary sexual maturation [5]. This hormone replacement therapy helps alleviate some of the symptoms associated with LCH.

Estrogen Replacement Therapy Some cases of LCH may require estrogen replacement therapy, particularly in individuals who have undergone gonadectomy (removal of the testes) [4].

Gene Therapy Recent studies have investigated gene therapy as a potential treatment for LCH. AAVDJ-Lhcgr gene therapy has shown promise in recovering testosterone production and improving sexual development in affected individuals [6].

Other Medications Research has also explored the use of other medications, such as propofol, which can inhibit androgen production by rat Leydig cells [8]. However, more studies are needed to determine its efficacy and safety in treating LCH.

It's essential to note that each case of LCH is unique, and treatment plans may vary depending on individual circumstances. A team of medical specialists should be consulted to determine the most effective course of treatment for a specific patient.

References: [2] - Apr 1, 2010 [4] - by S Jahan · 2020 · Cited by 9 [5] - In those individuals who are raised as males, testosterone therapy is started at puberty to increase phallic size and induce secondary sexual maturation. [6] - AAVDJ‐Lhcgr gene therapy was well tolerated and resulted in significant recovery of testosterone production, substantial improvement in sexual development, and ... [8] - by Y Wang · 2019 · Cited by 7 — Here, we report that propofol, a widely used anesthetic, inhibits androgen production by rat Leydig cells.

Recommended Medications

  • Gene Therapy
  • Estrogen Replacement Therapy
  • Testosterone Therapy
  • Other Medications

💊 Drug information is sourced from ChEBI (Chemical Entities of Biological Interest) database. Always consult with a healthcare professional before starting any medication. Click on any medication name for detailed information.

Differential Diagnosis

Leydig cell hypoplasia (LCH) is a rare genetic disorder characterized by underdevelopment or insufficient growth of Leydig cells, leading to reduced testosterone production and impaired sexual differentiation in males. When considering the differential diagnosis for LCH, several conditions should be taken into account.

Conditions to Consider:

  • Congenital Adrenal Hyperplasia (CAH): This is a group of inherited disorders that affect the adrenal glands, leading to an overproduction or underproduction of hormones. CAH can cause similar symptoms to LCH, such as ambiguous genitalia and hormonal imbalances.
  • Rokitansky-Kuster-Hauser Syndrome: Also known as Mayer-Rokitansky-Küster-Hauser syndrome (MRKH), this is a rare genetic disorder that affects the development of the vagina and uterus. While it primarily affects females, it can also be considered in the differential diagnosis for LCH.
  • Lymphoma, Leukemia, Metastatic Disease, and Bilateral Primary Testicular Neoplasm: These conditions can cause similar symptoms to LCH, such as testicular swelling and hormonal imbalances.

Key Points:

  • Leydig cell hypoplasia is a rare genetic disorder that affects the development of Leydig cells in the testes.
  • The differential diagnosis for LCH includes CAH, Rokitansky-Kuster-Hauser Syndrome, lymphoma, leukemia, metastatic disease, and bilateral primary testicular neoplasm.
  • Accurate diagnosis requires a comprehensive evaluation of hormonal levels, genetic testing, and imaging studies.

References:

  • [1] Leydig cell hypoplasia refers to a condition characterized by underdevelopment or insufficient growth of Leydig cells, leading to reduced testosterone production and impaired sexual differentiation in males. ... the only other doncition in the differential diagnosis is CAIS).
  • [8] Other differential possibilities would include lymphoma, leukemia, metastatic disease, and bilateral primary testicular neoplasm.
  • [10] We wanted to emphasize the necessity of keeping Leydig cell hypoplasia in mind in the differential diagnosis of sexual development disorders in early childhood.

Additional Differential Diagnoses

Additional Information

oboInOwl#hasOBONamespace
disease_ontology
oboInOwl#id
DOID:0112259
core#notation
DOID:0112259
oboInOwl#hasDbXref
ORDO:755
oboInOwl#hasExactSynonym
46,XY DSD due to luteinizing hormone resistance or luteinizing hormone beta subunit deficiency
IAO_0000115
A pseudohermaphroditism that has_material_basis_in homozygous or compound heterozygous mutation in the LHCGR gene on chromosome 2p16.3.
rdf-schema#label
Leydig cell hypoplasia
rdf-schema#subClassOf
http://purl.obolibrary.org/obo/DOID_0112261
oboInOwl#inSubset
http://purl.obolibrary.org/obo/doid#DO_rare_slim
IDO_0000664
http://purl.obolibrary.org/obo/GENO_0000148
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
rdf-schema#domain
https://w3id.org/def/predibionto#has_symptom_6768
owl#annotatedSource
t388193

Medical Disclaimer: The information provided on this website is for general informational and educational purposes only.

It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with questions about your medical condition.